$44,957.84 speaking Payment -- AbbVie Inc to Dr. Joseph Carter
Neurologist Joseph Carter Receives Over $44,000 in Speaker Compensation from AbbVie Inc.
This page provides a detailed analysis of a $44,957.84 speaking payment from AbbVie Inc to Dr. Joseph Carter. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $44,957.84 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | AbbVie Inc |
| Physician | Dr. Joseph Carter |
| NPI Number | 1668089380 |
| Physician Specialty | Neurology |
| Location | City, WA |
| Date of Payment | 2024-07-22 |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AbbVie Inc made a $45.0K speaking payment to Joseph Carter, a Neurology specialist in City, WA. Dr. Joseph Carter received a total of $44,957.84 from AbbVie Inc. in 2024. The payment was for serving as faculty or a speaker, indicating engagement in educational or promotional activities. This payment represents a significant financial interaction between a pharmaceutical company and a practicing neurologist.
Patient Guidance: What This Payment Means for You
Patients should be aware that their doctors may receive compensation from pharmaceutical companies for speaking engagements, which could potentially influence their prescribing habits. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For a neurologist, receiving over $44,000 for speaking engagements from a single pharmaceutical company is a high amount compared to typical speaker fees, suggesting extensive involvement.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements, which mandate disclosure of payments made by drug and device manufacturers to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- neurology
- speaker-fees
- abbvie-inc
- open-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $45.0K payment for?
This was a speaking payment of $45.0K from AbbVie Inc to Joseph Carter, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Joseph Carter accept pharmaceutical money?
Yes, Joseph Carter received this $45.0K payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Joseph Carter's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $45.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Neurology?
To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Joseph Carter's relationship with AbbVie Inc?
The payment amount is substantial, suggesting a significant role or series of engagements. This $45.0K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Neurology?
The payment type is 'speaking,' which often involves presenting information about pharmaceutical products.
What should patients do after learning about this payment?
Patients should be aware that their doctors may receive compensation from pharmaceutical companies for speaking engagements, which could potentially influence their prescribing habits.
What else should I know about this speaking payment?
The date of payment falls within the current reporting year, making it highly relevant.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.